GLP-1 Results, Honestly: What the Timeline Really Looks Like

The photo skips the part you're living in

The before-and-after image is a lie of omission. Not the numbers — the numbers are often real — but the timeline. Two photos separated by a caption erase the fourteen months in between: the first weeks when almost nothing moves, the middle stretch when the scale finally slopes, the plateau that arrives and feels like failure, and the maintenance that is supposed to be the point. If you are three weeks in and down four pounds, wondering whether you are the one person the drug does not work for, the problem is not your body. It is that no one showed you the actual curve.

So here is the curve, drawn from the trials that measured it week by week rather than end to end.

Weeks 1 to 4: the drug is not "not working"

The first month is the lowest dose — deliberately. GLP-1s are titrated upward slowly, starting well below the therapeutic dose, precisely to blunt the nausea that comes with dose increases. That means the first weeks are as much about your gut adjusting as about weight coming off. Some women lose a few pounds early, largely water and appetite; some lose almost nothing. Both are normal. In the pivotal trials the meaningful weight loss accrued over months, not weeks, because the dose itself took months to climb. Judging the drug at week three is judging a book by its title page. If the early nausea is the hard part, our first-timer's guide to starting a GLP-1 covers what actually helps.

One thing often does move immediately, and it is the wrong thing to weigh. Researchers ran qualitative interviews with 86 adults as they came out of the SURMOUNT-4 tirzepatide trial — 83% of them women, mean age 50. Seventy-eight of those participants described their appetite dropping, and one gave the timing plainly: "Almost immediately, it suppressed my appetite." Others described the change in terms that had nothing to do with a number — "eating to live, instead of living to eat," and, from one woman, "like a whole different person, physically and mentally"⁶. In month one you may well be feeling the drug work while the scale has not caught up. Those are two different clocks, and only one of them is in your bathroom.

Months 2 to 6: the slope you were promised

This is where the trajectory earns the headlines. In STEP 1, adults on semaglutide lost a mean of 14.9% of their body weight over 68 weeks, against 2.4% on placebo, and it came off as a steady slope through most of that first year — not a cliff in month one¹. In SURMOUNT-1, tirzepatide at the top 15 mg dose reached −20.9% over 72 weeks, against −3.1% on placebo, on the same kind of gradual curve². When the two drugs were finally put head-to-head in SURMOUNT-5 — 751 adults randomized to the maximum tolerated dose of one or the other — tirzepatide averaged −20.2% and semaglutide −13.7% over 72 weeks³. Different destinations, same shape of journey: a long, mostly steady descent measured in seasons, not weeks.

Keep the placebo arms in view, because they are what the shape is measured against. The same diet advice, the same activity advice, the same 68 weeks of trying produced 2.4%. That is the honest size of the gap the medication is filling.

The honest footnote every average hides: these are group means. Some women in these very trials lost far more; some far less. The trajectory is a reliable shape, not a personal guarantee, and where your own line lands depends on your body, your dose, and whether you can stay on long enough to reach the therapeutic range.

That escalation shows up on the invoice, too, when a provider prices by dose. WePeptideRx publishes a ladder that tracks the same climb — $189/mo at the entry dose up to $299/mo for semaglutide, or $199/mo up to $389/mo for tirzepatide at the top tier — so the bill rises in step with the dose instead of arriving as a surprise partway through the year. Remi Meds runs the steepest version of this we've found: tirzepatide alone climbs from $349/mo at the entry dose to $649/mo at 11.25mg, a $300 swing on one molecule. Fierce Health shows the other trap worth watching for — a confirmed "from $197/mo" microdose rate against a struck-through $591 regular price, with its standard-dose tiers priced too unclearly to quote at all. Ascend Vitality and Heros Health take the opposite shape — a flat rate regardless of dose, discounted instead for committing to a longer term (a 6-month plan at Ascend Vitality, a 3-month plan at Heros Health), so the bill tracks your commitment length, not your climbing dose.

Months 6 to 12+: meet the plateau

Somewhere in the second half of the first year, most people's weight loss slows sharply. This is the moment that breaks the most people, because it feels like the drug stopped working.

The maintenance trials let you see the deceleration in actual numbers, because both of them ran a stretch on the drug and then measured a second stretch on the drug. In STEP 4, participants lost a mean 10.6% in their first 20 weeks on semaglutide — then, staying on it, a further 7.9% over the next 48 weeks⁴. In SURMOUNT-4, a 36-week lead-in on tirzepatide produced a mean 20.9% reduction; over the following 52 weeks of continued treatment, participants lost a further 5.5%⁵.

Read those as rates rather than totals and the shape is unmistakable. The loss does not stop — in both trials people on the drug kept going down, and in SURMOUNT-4 the total reached 25.3% by week 88. But the pace in the second year is a fraction of the pace in the first. So what feels like a wall is really the curve bending, and the honest version is neither "you have plateaued forever" nor "push harder and it will resume." It is a checkpoint to discuss dose, muscle and habits with your clinician — not a verdict, and not a reason to quit.

The part the photos never show: after

Here is the fact that should reframe the whole timeline. These drugs are studied as ongoing treatments, not courses you complete — and both maintenance trials had a second arm, which is where the reframing lives. In STEP 4, the people switched from semaglutide to placebo did not merely stop losing; they regained 6.9% over 48 weeks while the continuing group lost 7.9%⁴. In SURMOUNT-4 the split was starker still: continuing tirzepatide took another 5.5% off, switching to placebo put 14.0% back on, and 89.5% of those who stayed on the drug held at least four-fifths of what they had lost, against 16.6% of those who came off⁵. The "after" photo, in other words, is not an endpoint — it is a weigh-station, and staying there is its own phase with its own plan. We treat that stretch honestly in coming off a GLP-1 and the rebound question.

For a mother, this changes which question matters. Not "how fast will the weight come off" but "can I sustain this — the cost, the routine, the clinical support — for as long as the biology needs?" The cost curve, in particular, climbs as the dose does; we map it in the true cost as the dose climbs.

What a realistic year actually looks like

• Weeks 1–4: low dose, gut adjusting, little scale movement — but appetite often changes almost at once⁶. Normal.
• Months 2–6: the steady slope; most of the visible change lives here^1,2.
• Months 6–12: loss continues but the rate falls hard — roughly a quarter of the first-year pace in the maintenance trials^4,5.
• Beyond: maintenance is an active phase; stopping without a plan invites regain^4,5.

The women who are happiest a year in are the ones who set their expectations to this curve instead of the two-photo version — and who chose a program that stays with them across all of it. That is easier with real monitoring behind it: 9amHealth bundles labs into its $149/mo membership rather than leaving you to chase your own numbers, and Optimized Health titrates against lab work too — though its own homepage overstates the medication as "FDA-approved" when the compounded version it dispenses is not.